Written by: Lisa Raff, PharmD, BCPS, BCOP Northwest Oncology & Hematology
Download Here

Treatment options for patients with carcinoid syndrome diarrhea that is refractory to somatostatin analog (SSA) therapy are limited. A first in class oral tryptophan hydroxylase inhibitor, telotristat ethyl, was approved in February for 2017 for use in combination with SSA therapy in adults with carcinoid syndrome diarrhea inadequately treated with SSA. Continue reading Telotristat ethyl: Carcinoid Syndrome Diarrhea

Read More